Global Renal Insufficiency Industry Outlook 2025-2029: Market Set to Cross $18.52 Billion Milestone

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Renal Insufficiency Market Size By 2025?
The scope of the renal insufficiency market has expanded significantly over recent times, projected to increase its valuation from $10.87 billion in 2024 to $12.1 billion the following year, reflecting an 11.4% compound annual growth rate. This upward trajectory during the past period stems from a confluence of factors, including a greater incidence of hypertension and diabetes, the escalating spread of chronic kidney disease (CKD), a rise in occurrences of urinary tract blockages, the expanding demographic of older individuals, and heightened public knowledge and instruction concerning renal wellness.

How Big Is the Renal Insufficiency Market Size Expected to Grow by 2029?
Projections indicate that the market for renal insufficiency will experience swift expansion in the approaching years, achieving a valuation of $18.52 billion by 2029, driven by an 11.2% compound annual growth rate. This upward trajectory throughout the projection timeframe is fueled by a rising incidence of acute kidney injuries, greater utilization of treatments administered at home, escalating spending in healthcare, along with increased funding channeled into research and development activities across the sector. Key movements anticipated during this period encompass significant strides in medical technology, enhancements in therapeutic approaches and available treatment modalities, the incorporation of personalized medical strategies, progress in dialysis systems technology, and the creation of novel and inventive pharmaceutical products.

View the full report here:
https://www.thebusinessresearchcompany.com/report/renal-insufficiency-global-market-report

Which Key Market Drivers Powering Renal Insufficiency Market Expansion and Growth?
Anticipated expansion in the renal insufficiency market is being fueled by the rising prevalence of individuals suffering from hypertension and diabetes. These health conditions, high blood pressure and diabetes, are linked to various causes including inadequate nutrition, insufficient exercise, excessive body weight, inherited tendencies, and the gradual aging of the populace. Specifically, hypertension harms the kidney's vascular system through the development of scar tissue and diminished filtering capacity, whereas elevated blood sugar levels in diabetes cause the renal vessels to thicken and become strained; both pathologies contribute to the progression of kidney impairment resulting in renal insufficiency. To illustrate this trend, data from the National Health Service, a governing body in the United Kingdom, indicated a surge of 71,120 new diagnoses of high blood pressure in the South East region by December 2023, representing a 5.4 percent increase relative to December 2022, as reported in May 2024. Furthermore, the British Diabetic Association, a charitable entity within the UK, stated in April 2023 that the UK populace includes 4.3 million individuals officially diagnosed with diabetes. Consequently, the escalating incidence of both hypertension and diabetes serves as the primary momentum behind the market's advancement in the renal insufficiency sector.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21271&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Renal Insufficiency Market?
Leading firms within the renal insufficiency market are focusing on the creation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a means to combat renal and cardiovascular issues observed in individuals suffering from diabetes and chronic kidney disease (CKD). GLP-1 RAs function by enhancing blood sugar regulation, decreasing inflammatory responses, and mitigating oxidative stress within the renal system, which collectively serves to decelerate the advancement of kidney impairment. To illustrate this trend, Novo Nordisk, a pharmaceutical entity headquartered in Denmark, secured validation from the Food and Drug Administration (FDA) in January 2025 for its product, Ozempic (semaglutide), specifically for decreasing the likelihood of kidney disease progression, the onset of kidney failure, and subsequent cardiovascular mortality among adults diagnosed with both type 2 diabetes and CKD. This regulatory milestone underscores the increasing significance attributed to GLP-1 RAs as a combined therapeutic strategy for managing both diabetic conditions and renal insufficiency, thereby fulfilling vital requirements for patients experiencing progressive CKD.

What Are the Emerging Segments in the Renal Insufficiency Market?
The renal insufficiencymarket covered in this report is segmented -

1) By Treatment Type: Medications; Dialysis; Kidney Transplantation; Other Treatment Types
2) By Disease Stage: Chronic Kidney Disease (CKD) Stages; End-Stage Renal Disease (ESRD)
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End-User: Dialysis Centers; Hospital And Clinics; Research And Academic Institutes

Subsegments:
1) By Medications: Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Diuretics; Erythropoiesis-Stimulating Agents (ESAs); Phosphate Binders; Sodium Bicarbonate
2) By Dialysis: Hemodialysis; Peritoneal Dialysis; Home Dialysis; Continuous Renal Replacement Therapy (CRRT)
3) By Kidney Transplantation: Living Donor Kidney Transplant; Deceased Donor Kidney Transplant; Kidney Transplant Immunosuppressive Therapy
4) By Other Treatment Types: Lifestyle And Dietary Modifications; Stem Cell Therapy; Gene Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21271&type=smp

Who Are the Global Leaders in the Renal Insufficiency Market?
Major companies operating in the renal insufficiency market are Kaiser Permanente, Johnson & Johnson, Roche Holding AG, Sanofi S.A., Abbott Laboratories, Medtronic plc, Amgen Inc., Asahi Kasei Medical Co. Ltd., Fujifilm Holdings Corporation, Fresenius Medical Care, Toray Industries Inc., Baxter International Inc., Boehringer Ingelheim, DaVita Inc., Eisai Co. Ltd., Nipro Corporation, Biocon Limited, HemoCue AB, Rockwell Medical, Mitsubishi Tanabe Pharma Corporation, Sorin Group.

Which are the Top Profitable Regional Markets for the Renal Insufficiency Industry?
North America was the largest region in the renal insufficiency market in 2024. The regions covered in the renal insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21271

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.